CTOs on the Move

Spirovant

www.spirovant.com

 
Spirovant is a gene therapy company focused on changing the course of cystic fibrosis and other respiratory diseases. The company`s current investigational gene therapy technologies are designed to overcome the historical barriers that have prevented effective genetic treatments for cystic fibrosis. Spirovant`s lead programs are in development for cystic fibrosis. Spirovant is a wholly owned subsidiary of Sumitovant Biopharma Ltd., which is itself a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Spirovant is located in Philadelphia, PA.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.spirovant.com
  • 3675 Market Street Suite 200
    Philadelphia, PA USA 19104
  • Phone: 267.244.8206

Executives

Name Title Contact Details
Eric Pastor
Senior Vice President of Technical Development and Operations Profile

Similar Companies

Premera

Premera is a Mountlake Terrace, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NovoBiotic Pharmaceuticals

NovoBiotic Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chinook Therapeutics

Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $100 billion in annual costs.

Trident Health System

Trident Health is the leading provider of laboratory and mobile imaging services to the long term care community in the US. Operating in 43 states, we currently provide these services to more than 5,000 of the 16,000+ long term care facilities in the US.

Avectas

Avectas is a cell engineering technology business developing a unique delivery platform to enable the ex vivo manufacture of gene-modified cell therapy products, which will retain high in vivo functionality. Our vision is to position the non-viral SOLUPORE® cell engineering technology to be integrated into manufacturing processes for multiple autologous and allogeneic therapies and commercialised through development and license agreements.